Technology | June 17, 2011

FDA Clears New Endologix Low-Profile Stent Graft

June 17, 2011 — Endologix Inc. received U.S. Food and Drug Administration (FDA) approval for AFX Endovascular AAA System for the treatment of abdominal aortic aneurysms (AAA). The company is introducing AFX at the annual meeting of the Society for Vascular Surgery (SVS),  June 16-18, 2011 in Chicago.

AFX builds upon previous anatomical fixation technology with a new low-profile, highly precise delivery system and a state-of-the-art, proprietary stent graft material (STRATA). The key features of the AFX System include:

• Low-profile 17 French introducer sheath – The entire family of AFX stent grafts, which range in diameter from 13 to 34 millimeters, are delivered through a low profile, hydrophilically coated 17 French introducer sheath – eliminating the need for exchanges. This sheath technology, combined with the system's percutaneous (9 French) contralateral access, makes AFX the lowest-profile device approved in the U.S. for the treatment of the most common AAAs – those with aortic neck diameters of 22 millimeters or larger.

• Precise delivery and deployment – The AFX delivery system features an ergonomic dial mechanism that provides physicians with precise, controlled stent graft positioning and deployment.

• STRATA expanded polytetrafluoroethylene (ePTFE) graft – AFX stent grafts are constructed using the new STRATA graft material. STRATA is a durable, highly conformable material featuring enhanced stent graft sealing technology.

In addition to AFX, the company's complete product portfolio will be highlighted at the SVS annual meeting. This includes the investigational Nellix Endovascular System and the Ventana Fenestrated Stent Graft System, both of which will be featured in symposia at SVS.

For more information: www.endologix.com 

Related Content

FDA Grants Breakthrough Device Designation for Valiant Thoracoabdominal Aortic Aneurysm Stent Graft
News | Stent Grafts | October 09, 2019
Medtronic plc announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA...
PQ Bypass Granted IDE Approval to Start TORUS SFA Stent Graft Pivotal Study
News | Stent Grafts | October 08, 2019
PQ Bypass Inc. announced it has received full approval of its investigational device exemption (IDE) trial of the...
First U.S. Patient Receives Gore Tag Conformable Thoracic Stent Graft With Active Control
News | Stent Grafts | July 10, 2019
W. L. Gore & Associates Inc. (Gore) announced the first U.S. implant of the Gore Tag Conformable Thoracic Stent...
Gore Receives FDA Approval for Gore Tag Conformable Thoracic Stent Graft
Technology | Stent Grafts | May 15, 2019
W. L. Gore & Associates Inc. (Gore) announced the U.S. Food and Drug Administration (FDA) has granted regulatory...
Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028
News | Stent Grafts | February 14, 2019
Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through...
Medtronic Receives FDA Approval for Valiant Navion Thoracic Stent Graft System
Technology | Stent Grafts | February 07, 2019
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for the Valiant Navion thoracic stent...
Endologix Ends Unrestricted Sales and Use of Nellix System
News | Stent Grafts | January 07, 2019
January 7, 2019 — Endologix Inc.
Endologix Reports Positive One-Year Results From the Ovation LUCY Study
News | Stent Grafts | July 16, 2018
Endologix Inc. announced one-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for...
FDA Committee Votes in Favor of Incraft AAA Stent Graft System
News | Stent Grafts | June 13, 2018
Cardinal Health announced that its Incraft Abdominal Aortic Aneurysm (AAA) Stent Graft System has received a favorable...
First Patient Enrolled in Gore Excluder Investigational Study
News | Stent Grafts | January 08, 2018
January 8, 2018 — W. L. Gore & Associates Inc.